H epatitis C virus (HCV) infection has emerged as a serious health problem in the United States, and is one of the most significant causes of chronic liver disease in this country (National Institute of Allergy and Infectious Diseases [NIAID] , 1998; National Institute for Occupational Safety and Health, 1999) . Additionally, HCV poses a threat of occupational acquisition by percutaneous or permucosal exposure to blood by workers in health care settings (Alter, 1994) . Therefore, the development of hepatitis C postexposure policies for health care workers is essential. Such policies must consider legal and ethical issues and health outcomes in their development.
This article describes a proposed policy and procedure for postexposure testing of health care workers for HCV infection in a hospital setting. A review of literature and discussion oflegal and ethical issues and health outcomes are presented. The article concludes with a proposed policy, procedure, and detailed description of the steps for implementation that can be used as a guide in formulating programs.
LITERATURE REVIEW
Approximately 4 million Americans, or 1.8% of the U.S. population, are infected with HCV (NIAID, 1998) . HCV infection causes an estimated 8,000 to 10,000 deaths
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Dr. Haiduven is Infection Control Supervisor, Santa Clara Valley Medical Center, San Jose, CA. 370 annually in the United States (NIAID, 1998) . Most individuals with hepatitis C are chronically infected and may be unaware of the infection because they are not clinically ill. Infected individuals serve as a source of transmission to others. They are at risk for chronic liver disease or other HCV related chronic diseases during the first two or more decades following initial infection (Centers for Disease Control and Prevention [CDC] , 1998). The only Food and Drug Administration (FDA) approved drug for the treatment of chronic hepatitis C infection is interferon. Combination therapy using interferon and ribavirin is FDA approved for individuals who have relapsed following interferon therapy (CDC, 1998) . This therapy is effective in only 15% to 25% of individuals, is fraught with numerous side effects, and a has a 50% relapse rate when therapy is stopped (CDC, 1998; Fried, 1995) .
Risk factors associated with transmission of this disease identified from case control studies are (Alter, 1982 (Alter, , 1997 (Alter, , 1989 CDC, 1998) :
• Injection drug use.
• Employment in client care or clinical laboratory work.
• Exposure to a sex partner or household member with a history of hepatitis.
• Exposure to multiple sex partners.
• Low socioeconomic level.
HCV seroconversion has been documented in health care workers after percutaneous needlestick exposure, ranging from 2% to 10% of percutaneous contacts (Dana, 1994; Lanphear, 1994; MacDonald, 1996) . Thus, health care workers who provide care for clients in high risk categories and who perform procedures involving needles and blood are at risk for occupational acquisition of hepatitis C infection. Recently released guidelines from the United States Public Health Service (USPHS) and the final draft of the revision of the California Occupational Safety and Health Administration's (CaUOSHA) Bloodbome Pathogens (BBP) Standard provide a template for health care institutions for postexposure policies and procedures for hepatitis C infection (CDC, 1998; OSHA, 1998) .
LEGAL ISSUES
Currently, testing of health care workers for hepatitis C infection under any circumstances is not required by law in any document. The Occupational Safety and Health Administration's (OSHA) existing federal Bloodbome Pathogens Standard does not contain language for hepatitis C (OSHA, 1991) . However, the California BBP Standard has undergone a revision that includes hepatitis C wording in the section on postexposure evaluation and follow up as, "Postexposure evaluation shall include hepatitis C evaluation and shall be repeated at intervals recommended by the U.S. Public Health Service" (OSHA, 1998) .
As illustrated by the previous statement, a source frequently used when developing policies and procedures related to infection control and employee health for health care workers is the CDC. For example, their guidelines for prevention of HlV using universal precautions were published prior to the OSHA BBP Standard and contain many recommendations retained in the OSHA standard. Similarly, CDC and USPHS Guidelines for the Prevention and Control of Tuberculosis have been adopted by numerous health care facilities. The OSHA tuberculosis standard is still undergoing revision. The CDC and the USPHS recently published Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV Related Chronic Disease (CDC, 1998) . The scope of these guidelines extends to groups at high risk for developing hepatitis C, such as injection drug users and recipients of blood and tissue donations, as well as to individuals who sustain percutaneous exposures to blood in health care settings.
The scope of this article is limited to occupational HCV exposure in the health care setting. The specific recommendations from the 1998 CDC guidelines are as follows:
Individual institutions should establish policies and procedures for HCY testing of persons after percutaneous or pennucosal exposures to blood and ensure that all personnel are familiar with these policies and procedures. Health-care professionals who provide care to persons exposed to HCY in the occupational setting should be knowledgeable regarding the risk for HCY infection and appropriate counseling, testing, and medical follow up. Immune Globulin and antiviral agents are not recommended for postexposure prophylaxis of hepatitis C. Limited data indicate that antiviral therapy might be beneficial when started early in the course of HCY infection, but no guidelines exist for administration of therapy during the acute phase of the infection. When HCY infection is identified early, the individual should be referred for medical management to a specialist knowledgeable in this area. Routine HCY testing is not recommended for healthcare, emergency medical, and public safety AUGUST 2000, VOL.48, NO.8 In health care workers, prevention of transmission [of the hepatitis C virus] can be accomplished by education, counseling, and use ofsafety devices. workers unless they have risk factors for infection (CDC, 1998) .
These guidelines are comprehensive, current, compiled by a list of experts in the field, and extensively referenced. Because this wording has been retained in the final version of the OSHA BBP Standard, following the USPHS guidelines currently carries the force of a standard. Thus, it is prudent to adopt these guidelines. One potential outcome related to workers' compensation is that testing of the source client and the injured employee at the time of a blood exposure coupled with follow up testing may identify cases of occupational infection with hepatitis C. Thus, a health care worker may acquire HCV infection "arising out of the course of employment" and must be compensated for costs such as medical, rehabilitation, and lost wages (Levy, 1995) . Health care institutions that do not adopt the USPHS guidelines and are inspected by CaUOSHA officials can be cited and fined.
ETHICAL ISSUES
Currently no vaccine is available for the prevention of HCV infection. In fact, the only means of preventing new cases of hepatitis C are to screen the blood supply, encourage health professionals to take blood and body fluid precautions, and to inform people about high risk behaviors (NIAID, 1998) . In health care workers, prevention of transmission can be accomplished by education, counseling, and use of safety devices. Thus, health care institutions have an ethical and moral responsibility to educate those at high risk for the disease about screening, treatment and prevention, and to identify and compensate health care workers who acquire HCV in the course of their employment.
The principle of beneficence is defined as "the requirement that health care professionals act in the best interest of the worker" (Rogers, 1994) . This principle applies to the education of health care workers upon initial hire and annually, to testing of the employee for HCV postexposure, and to risk reduction and transmission prevention counseling (Hulley, 1988; Rogers, 1994) . Because laboratory tests are available to identify HCV infection, these tests should be provided to individuals who might be infected to allow for early identification, treatment, and prevention of transmission to others. At the least, prerequisites for ethical screening programs should include use of high quality laboratory services, appropriate counseling before and after screening, and confidentiality in handling results (Rogers, 1994) .
The principle of autonomy refers to an individual's "right to self determination or personal liberty" (Rogers, 1994) . This principle applies in obtaining informed consent, confidentiality of test results, and the right of the exposed employee to know the HCV status of the source client (Rogers, 1994) . When testing an employee for HCV at the time of a particular occupational exposure, there is a possibility of identifying hepatitis C infection that occurred prior to the time of the most current exposure. This indicates the employee did not acquire the disease from that particular exposure and it mayor may not be work related. An ethical dilemma arises because the institution may not financially support further treatment of non-occupational infection.
The other dilemma is that the infection may have been acquired from a previous undocumented exposure. However, in either case employees still need to be counseled about transmission, and referred to their own health care provider who can subsequently refer to a specialist for possible treatment. The health care provider has a moral and ethical responsibility to counsel and educate these employees and to protect their confidentiality, illustrating the principles of beneficence and autonomy.
The occupational health nurse who counsels an infected employee who did not acquire an infection from work must protect that information and not divulge it unless indicated under the Code of Ethics, either upon written consent of the employee or as required or permitted by law (Levy, 1995) . Finally, the occupational health nurse must not allow personal feelings about intravenous drug abuse or multiple sexual partners (risk factors for non-occupationally acquired HCV infection) to interfere with counseling employees. Thus, the fourth ethical principle of justice, defined as "directed toward treating employees fairly, equally, and without discrimination," (Rogers, 1994) applies. This principle is also part of the Code of Ethics of the American Association of Occupational Health Nurses, as illustrated by the statement:
The occupational health nurse provides health care in the work environment with regard for human dignity and client rights, unrestricted by considerations of social or economic status, national origin, race, religion, age, sex, or the nature of the health status" (cited in Levy, 1995) .
PROPOSED POLICY
This section includes a proposed policy and procedure for use in the hospital setting. Included are statements of philosophy and purpose, objectives, policy components, and procedure steps. The USPHS guidelines are incorporated into this policy statement.
Philosophy and Purpose
The institution's philosophy about occupational safety and health is that the safest environment possible shall be provided to employees. The prevention or 372 reduction of transmission of infections among employees, patients, and visitors is a central purpose in infection control/employee health policies and procedures of the institution.
Objectives
• To provide prompt postexposure management of occupational HCV exposures to health care workers, according to the guidelines of the USPHS and in compliance with OSHA's BBP Standard.
• To identify and counsel high risk patients and employees about prevention of this disease.
• To provide the opportunity for early identification and referral to appropriate specialists of employees with occupational HCV acquisition; to refer infected patients and non-occupationally infected health care workers to their own health care providers.
Policy
• Universal precautions shall be followed consistently by all health care workers in the care of all patients because medical history and examination may not reliably identify all patients infected with HCV or other bloodbome pathogens.
• In the event of an occupational exposure to blood, the institution shall make available first aid, postexposure evaluation, and follow up testing to all employees.
• Postexposure evaluation, counseling, and follow up testing shall be conducted using the USPHS guidelines and CaVOSHA BBP Standard.
• The source patient shall be evaluated for HCV infection and if positive, the health care worker shall be tested for the presence of the infection at baseline and at intervals suggested by the USPHS.
• Employees who acquire HCV infection from an occupational exposure shall be compensated for medical care, follow up testing, and lost wages that result according to workers' compensation laws.
• Currently, immune globulin or antiviral agents are not recommended for postexposure prophylaxis.
• Confidentiality of all information on employees related to counseling and testing for HCV infection will be maintained.
• Routine testing for HCV infection is recommended only as follow up for a specific exposure. Therefore, screening of health care workers for HCV infection will not be conducted as part of the preplacement physical examination. Employees who wish to be screened for HCV infection outside of the exposure situation may arrange to do so at their own expense.
PROCEDURE STEPS
Definitions and abbreviations related to this procedure are included in the Sidebar on page 373. In the event of a percutaneous or mucocutaneous exposure, the employee will:
• Immediately apply first aid to the affected site. For a percutaneous injury, wash the site vigorously with soap and water. For a mucocutaneous exposure, flush the area thoroughly with water.
• Report the exposure to the direct supervisor. Report to employee health (EH) (Monday through Friday daytime hours) or emergency department (outside of EH hours).
The employee health or emergency department clinician will:
• Determine if source patient is known. If known, contact the attending health care provider of source patient to determine if source is already documented as infected with HCY. If yes, the EH or emergency department will then request the health care provider draw blood of source patient to perform confirmatory test of source patient for hepatitis C by RIBA method. If the source patient is not known to be positive, request health care provider to draw blood for ALT, anti-HCY, and HCY RT-PCR test. If unknown source, proceed to next step.
• If the source patient's baseline tests are positive for HCY infection, or if source is unknown, draw blood of employee for baseline ALT and anti-HCY.
• Counsel the employee about the risk of infection and precautions to prevent secondary transmission of hepatitis C during the follow up period (e.g., not sharing razors or toothbrushes, avoidance of injection drug use by shared needles, use of condoms).
• If the employee has been exposed to known positive HCY source, draw blood and test for ALT and anti-HCY again at 3 months. If positive, counsel about precautions to prevent transmission and refer to a physician specializing in diseases of the liver at no cost to the employee. If employee exposed to unknown source has positive baseline ALT or anti-HCY, counsel employee of precautions to follow for prevention of transmission and refer to own health care provider for follow up.
• If employee exposed to positive HCY source has negative laboratory tests at 3 months, test again for anti-HCY and ALT at 6 months. If positive, refer to a physician specializing in diseases of the liver at no cost to the employee. Counsel again about precautions to prevent transmission.
• If laboratory tests of employee are negative at 6 months, 'consider the follow up period complete. Exception: If the source patient is HIY and anti-HCY positive, the follow up period for testing of the employee will be extended to 12 months.
• Establish and maintain an accurate record for each employee with occupational exposure in accordance with the CalIOSHA BBP Standard. Maintain confidentiality by keeping details of the exposure in a separate, locked file in employee health department.
The institution will: • Mandate the practice of universal precautions by all employees.
• Provide initial and annual education about HCY infection and other bloodborne pathogens and provide personal protective equipment (PPE) and safety devices for all employees involved in procedures with potential for exposure to blood or other body fluids. Education, PPE, and safety devices will be provided at no cost to the employee.
• Compensate employees with occupational acquisition of HCY infection according to workers' compensation laws. 
POLICY IMPLEMENTATION
To facilitate the development and implementation of such a policy, certain steps should be taken. The following steps have been instrumental in the development of the author's own institutional policy.
Anticipation of the Polley's Impact
The policy will impact specific issues and departments. These include infection control and employee health management of the policy, support services from the laboratory to perform the HCY testing, cost and administrative support of these costs, postexposure employee counseling, referral of infected employees for further treatment, and public health implications. The author recommends beginning with this step to identify departments needed for a successful task force to address concerns and issues.
Development of a Task Force
A task force with representatives from the above mentioned departments should be recruited. As the infection control committee of a hospital is often charged with such policy and procedure formulation, a subcommittee might be a prudent avenue for the task force. A logical chair for this subcommittee is someone who is knowl-It is important lor inlection control and employee health to monitor the literature and regulatory standards lor changes requiring policy revision.
edgeable in HCV issues as they relate to postexposure in the health care setting as well someone who is skillful in conducting meetings. The current chair of the infection control committee or the head of the EH are reasonable candidates for this task. The first task force meeting should identify the charge of the committee, an action plan, and a timetable for completion of the action plan.
Literature Review
Currently, there has been an increase in the volume of literature related to the topic of HCV, recent CDC recommendations, and inclusion of hepatitis C in the recent revision of the CalIOSHA BBP Standard. It is imperative for those involved in the policy formulation to be informed about the most current information. A packet of literature should be disseminated at or prior to the first task force meeting, and members requested to review the information by the time of the second meeting.
DISCUSSION
After task force members have read the literature, a discussion of ethical and legal issues, health consequences, and cost can be conducted. Short and long term goals should also be developed for the policy at this time.
Development of Written Policy and
Procedure Based on the discussion and consensus of the task force on all pertinent issues, a written policy and procedure should be developed and disseminated to the task force for review and comments. Another task force meeting should be held to discuss the proposed policy. The policy should be revised as necessary, then presented to the entire infection control committee for approval. At this time, other departments and issues that may be impacted by the policy may emerge, and there will be an opportunity to discuss these and revise the policy if necessary. Then the process for administrative approval of the policy and procedure can be initiated.
Communication to Affected Employees
For a policy to be effective, it must be shared and understood. Written memoranda alerting employees to the policy, summarizing the important components and how employees will be affected, should be distributed. The format for such communication can be flyers posted on the units, employee newsletters, and paycheck memos. Copies of the proposed policy and procedure
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should also be communicated to the labor unions of affected employees.
Implementation of the Policy
After it is approved, the policy can be implemented. During the start up process, task force members should serve as resource individuals to identify and correct initial problems that may occur.
Ongoing Evaluation
After implementation, the policy and procedure should be evaluated on an ongoing basis. Informal surveys of employees who have been exposed to HCV, cost analyses of the laboratory testing methods, and discussions with infection control and employee health staff who have been administering the policy and procedure may be used in the evaluation. Task force members should present a report to the infection control board within 6 months to a year after policy implementation. This is a good time to make any necessary changes to the policy or procedure. As always, it is important for infection control and employee health to monitor the literature and regulatory standards for changes requiring policy revision.
Health Outcomes of Proposed Policy
More than 50% of individuals exposed to HCV develop chronic infection. Of those individuals chronically infected, approximately 20% to 30% will develop liver cirrhosis or hepatocellular carcinoma when followed for 20 to 30 years (Heintges, 1997) . Several potential health outcomes can result from this proposed policy. First, there is the possibility of identifying high risk patients and employees during exposure situations who would benefit from counseling about disease prevention. According to the CDC (1998):
Persons who inject drugs or who are at risk for STDs [sexually transmitted diseases] should be counseled about what they can do to minimize their risk for becoming infected or of transmitting infectious agents to others.
Because of the long period between infection and disease, many cases of hepatitis C are not identified until several decades after infection. Thus, the second outcome is the potential identification of patients and employees with HCV infection who might not have been identified if not for the exposure situation. These cases might also be identified before extensive damage from cirrhosis or liver disease has occurred, thus creating an opportunity for earlier treatment. According to the CDC (1998):
The immediate postexposure setting provides an opportunity to identify persons early in the course of their HeV infection. Studies indicate that interferon treatment begun early in the course of HeV infection is associated with a higher rate of resolved infection. However, no data exist indicating that treatment begun during the acute phase of infection is more effective than treatment begun early during the course of chronic HeV infection. ... interferon is not FDA approved for this indication. After a number of cases have been treated early, data can be collected about the efficacy of such early treatment. As a result of this second potential outcome, there is also opportunity for prevention of transmission of infection to others by instituting education to identified cases. Another potential outcome is the ability to more adequately quantify the risk of HCY transmission to health care workers from exposure situations after this policy has been implemented. The possibility also exists for identifying preventive and protective work practices for avoiding occupational acquisition of HCY infection. In summary, there are primary (prevention of disease, prevention of transmission to others), secondary (early detection of disease), and tertiary (treatment for disease) prevention opportunities with implementation of this policy.
CONCLUSION
Occupational exposure to HCY among health care workers is a problem warranting a comprehensive protocol for management. The recent issue of USPHS guidelines and the recent revision of the California OSHA BBP Standard have prompted the development of institutional policies to deal with this important problem. Legal, ethical, and health consequences of such policies must be considered. A sample policy statement for use in a health care setting has been provided, along with proposed steps for implementation. It is hoped this will assist occupational health care professionals involved in protocol development and management of health care workers with potential for HCY exposure.
